Navigation Links
New imaging technique visualizes cancer during surgery
Date:9/19/2011

Ovarian cancer is one of the most frequent forms of cancer that affect women. As tumors can initially grow unchecked in the abdomen without causing any major symptoms, patients are usually diagnosed at an advanced stage and have to undergo surgery plus chemotherapy. During the operation, surgeons attempt to remove all tumor deposits as this leads to improved patient prognosis. To do this, however, they primarily have to rely on visual inspection and palpation - an enormous challenge especially in the case of small tumor nests or remaining tumor borders after the primary tumor excision.

Yet surgeons could now be getting support from a new multispectral fluorescence imaging system developed by a team of researchers in Munich, headed by Vasilis Ntziachristos, Professor of Biological Imaging. A study carried out on nine patients with ovarian cancer has shown that the new system can be used to localize cancer cells during surgery. Before the operation, the patients were injected with folic acid chemically coupled to a green fluorescent dye. Most ovarian tumors have a protein molecule on their surface that bonds with folic acid and transports it inside the cell. This protein is known as the folate receptor alpha. During abdominal surgery, the surgeon can then shine a special laser light onto the patient's ovaries, causing the green-labeled folic acid inside the cancer cells to emit light. Healthy tissue remains dark.

The fluorescent cancer cells, however, cannot be detected by the naked eye. Three cameras, mounted on a pivoting support arm over the operating table, detect optical and fluorescent signals at multiple spectral bands and then correct for light variations due to illumination and tissue discolorations in order to provide truly accurate fluorescence images that can be simultaneously displayed with corresponding color images on monitors in the operating room. The surgeon can thus check whether all the cancer cells have been removed by inspecting for remnant fluorescence light. In eight of the nine patients, doctors were able to remove small clusters of tumor cells that might otherwise have gone undetected. The multispectral fluorescence imaging system has thus passed its first OR test. However, it will have to prove its value to improve clinical outcome in further operations before it can be deployed for routine surgical procedures.

The researchers in Munich and Groningen also want to further develop the camera system so it can be used to detect other forms of tumors during operations. Of significant importance in future developments is the ability to offer accurate fluorescence imaging so that data collected reflect true presence of disease. "The use of advanced, real-time optical technology will allow us to standardize data collection and accuracy so that studies performed at multiple clinical centers can be accurately compared and analyzed" explains Prof. Vasilis Ntziachristos. This is important for the clinical acceptance of the technology and its approval by regulatory agencies. In the future patient selection through personalized medicine approaches, for example by obtaining a molecular profile of the tumor of each patient, would further enable custom-tailored surgical treatment of improved accuracy. The team is also planning to build a version for minimally invasive operations.


'/>"/>

Contact: Dr. Markus Bernards
bernards@zv.tum.de
49-892-892-2562
Technische Universitaet Muenchen
Source:Eurekalert

Related medicine news :

1. Researchers utilize neuroimaging to show how brain uses objects to recognize scenes
2. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
3. New imaging test gives physicians better tool to diagnose Parkinsons disease
4. Imaging probe allows noninvasive detection of dangerous heart-valve infection
5. New high-speed 3-D imaging system holds potential for improved cancer screening
6. New CMU brain imaging research reveals why autistic individuals confuse pronouns
7. New imaging technique captures brain activity in patients with chronic low back pain
8. High-resolution imaging technology reveals cellular details of coronary arteries
9. IASLC: Adjunctive use of 3-D imaging system increases utility of CT lung cancer screening
10. Self-referral: A significant factor in imaging growth
11. Women May Be Getting Unneeded Heart Imaging Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... practices, is seeking candidates to serve on its Accreditation and Standards Committees ... “RadSite’s ultimate mission is improving image quality and reducing patient radiation dose,” ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: